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Abstract
Diabetes is the most common metabolic disorder affecting pregnancy. Its prevalence seems to be growing in
parallel with the epidemics of overweight and obesity. Recognizing and treating diabetes or any degree of glucose
intolerance in pregnancy results in lowering maternal and fetal complications. These patients present higher risk for
excessive weight gain, preeclampsia, cesarean sections, a high risk of developing type 2 diabetes and cardiovascular
disease in the future. Infants born to these mothers are at higher risk for macrosomia and birth trauma, and after
delivery, these infants have a higher risk of developing hypoglycemia, hypocalcemia, hyperbilirubinemia, respiratory
distress syndrome, polycythemia and subsequent obesity and type 2 diabetes. Despite several international
workshops and a lot of research there is still no unique approach to diagnose and treat diabetes in pregnancy.
Who, when and how to screen and diagnose diabetes in pregnancy has been debated in the literature for so many
decades and this debate seems to be endless. We present the evolution that screening and diagnosing diabetes in
pregnancy has had over time. Besides many evidence of the benefits these procedures bring, health care providers
still often prefer to use alternate criteria for this purpose. The myriad of maternal and fetal complications that could
be avoided with an appropriate and simple screening procedure are ignored. Robust clinical trials such as the
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study have shown how harmful can even slightly altered
blood glucose levels be, but it has been found a resistance in the adoption of the new criteria proposed after this
and other trials by many diabetes organizations. These organizations state that these new criteria would increase
the incidence of diabetes in pregnancy, would imply in longer term follow-up of these patients and would pose an
economic problem; they also state that alerting too many people in order to benefit a relatively few potential
diabetics would arise psychologic ill-effects. We think that health care providers should look for an uniformity in the
screening and diagnosing diabetes in pregnancy based on evidence based medicine and not on specialists
consensus.
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Introduction
Diabetes mellitus is a very ancient disease first described
in the Egyptian Ebers papyrus around 1500 BC; written
records of human pregnancy are still older. Although,
the first description of diabetes in pregnancy was done
by Bennewitz in 1824 in Germany [1]. He described a
clinical case of a woman with intensive thirst and recur-
rent glycosuria in three successive pregnancies. One of
her babies weighted almost 5,5 kg. Her urine contained
a big amount of saccharine matter (about 60 g per 0,20 L).
In 1846 a similar case was reported by Lever [2].
Before the discovery of insulin in 1922, infertility was
well recognized in women with diabetes. The suggested
causes of infertility present in these women were ame-
norrhea, uterus and Graafian follicles atrophy and mal-
nutrition [3,4]. Few reports of conceptions in women
with diabetes existed then; seven pregnancies in 114
women with diabetes [3], 55 in 427 women with diabetes
of childbearing age [5], and four in 190 married women
with diabetes [6]. After the discovery of insulin and its
use initiation in 1923, the pregnancy rate increased by
seven-fold in women with a short duration of the disease;
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women with a long duration of diabetes still remained
sterile or with low conception rates for a long time.
In 1882, Duncan in London, reported the outcomes of
pregnancy in 16 women with 22 pregnancies. High rates
of maternal and perinatal mortality were present: more
than 60% for the mothers and 47% for the newborns.
The observations and the findings he had following
these pregnancies allowed him to several conclusions
such as: that diabetes may develop during pregnancy;
diabetes may occur only during pregnancy, being absent
in other times; diabetes may cease with the termination
of pregnancy, recurring some time after birth; diabetes
may develop soon after parturition; diabetes may not re-
turn in a pregnancy occurring after its cure; pregnancy
may occur in the presence of diabetes; pregnancy and
delivery may be apparently unaffected in its healthy pro-
gress by diabetes and finally that pregnancy is likely to
be interrupted frequently by the fetus death [7].
Williams, Professor of Obstetrics in Baltimore, in 1909,
reported 66 cases from the literature. Fifty-five patients
had diabetes previous to the conception; nine patients de-
veloped diabetes after conception and in two the time of
onset was not certain. The mortality rates were still high,
being 27% at the time of delivery with around an add-
itional 23% dying within two years after delivery. The peri-
natal mortality rates varied from 27-53% [8]. The principal
focus of his manuscript was on the interpretation and the
diagnostic role of glycosuria in pregnancy, because at that
time the diagnosis of diabetes was based on the presence
of sugar in the urine. He showed that if a woman’s urine
had between 1 and 3 g /L of sugar, it was most likely to be
a physiologic condition, but a higher concentration was
suggestive of diabetes, particularly if present in early preg-
nancy or in the presence of symptoms. His study might
have been the first prospective screening program for dia-
betes in pregnancy [8].
The presence of glycosuria during pregnancy and its role
as diagnostic of asymptomatic diabetes was a strongly de-
bated subject by that time. In 1856, the presence of
physiological glycosuria in pregnancy and lactation was
first described [9], and in 1877 different types of sugar
were identified in the urine, being lactose the most fre-
quently type of sugar found in the urine of pregnant
women [10]. The incidence of true glycosuria varied from
10% to 100%; some authors believed that it represented
true diabetes and others that it was a benign condition.
The believe that it might represent true diabetes was based
on the fact that many women that presented glycosuria
had typical symptoms of diabetes such as polydpsia, poly-
uria, polyhydramnios and even adverse fetal outcomes [8].
The cause of glycosuria was unknown. Some suggested
that it was alimentary (caused by a greater absorption of
carbohydrates) or toxemic (caused by liver abnormal-
ities). Brocard, in 1898 demonstrated by the first time
that pregnant women were less tolerant to sugar com-
pared to non-pregnant women; he has found the pre-
sence of glycosuria 2 hours after the ingestion of 50 g of
glucose in 50% of pregnant women compared to 11%
found in non-pregnant women [11]. Glycosuria was also
found to be recurrent in successive pregnancies [11].
In order to solve this problem of classifying a woman
as having or not diabetes based on the glycosuria levels,
J.W.Williams recommended a follow-up of all mothers
that presented glycosuria for possible complications of
diabetes. He concluded that it was important to distin-
guish if the patient had a transient or a persistent glyco-
suria, to distinguish whether the sugar was lactose or
glucose. If glycosuria appears late in pregnancy, is less
than 2%, and not accompanied by symptoms, it is prob-
ably transient, of slight clinical significance and indicates
the patient should be carefully watched. However, if
glycosuria appears early in pregnancy and in large
amounts, it represents a more serious condition, because
it will make it difficult to diagnosis diabetes until after de-
livery. In cases of diabetes it will persist; the course of dia-
betes in pregnancy is variable, pregnancy may occur in
women with diabetes or diabetes may withdrawn manifest
during pregnancy and finally he suggested that if the
amount of glycosuria is large and cannot be controlled,
the induction of abortion or premature labor should be in-
dicated, even if the patient does not show severe symp-
toms [8].
Between 1920 and 1930 many reports have described
the presence of pancreatic abnormalities in stillborn in-
fants from mothers with diabetes, mainly hypertrophy of
Langerhans’ islands; which was suggested to occur as a
consequence of glucose transfer from the mother to the
fetus, to a poor maternal glucose control and the pos-
sible cause of severe neonatal hypoglycemia, that could
be fatal in a few days after birth [4,12].
After the discovery of insulin, and its use during preg-
nancy, many reports of its efficacy were done by many au-
thors [6,13-16]. Lambie in Edinburgh, in 1926, pertinently
concluded that when diabetes appears for the first time in
pregnancy, it usually manifests in the fifth or sixth month
and exceptionally before the fourth or after the eighth
month of gestation. He also suggested the 50 g oral glu-
cose challenge test (OGCT) for calculating the ketogenic-
antiketogenic balance [16]. Skipper in 1933, published a
vast review of the literature in the use of insulin in preg-
nancy and found a dramatic improvement in maternal
mortality and a modest impact on fetal and neonatal out-
comes and survival [6]. He then concluded that the use of
insulin has led to lower maternal mortality, but no reduc-
tion in fetal mortality; women with diabetes usually
present glucose intolerance during the latter months of
pregnancy; hypoglycemia is common in the puerperium
and may have serious consequences including coma; if a
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woman with diabetes receives an adequate treatment,
pregnancy should not be harmful; ketonuria is common in
badly treated cases; the most important cause of fetal
death is poor metabolic control, overdevelopment of the
fetus and presence of congenital malformations; every
pregnant woman with glycosuria should be investigated as
possibly having diabetes because it may appear during
pregnancy; a rigid control of diabetes through the eva-
luation of glycosuria is of great importance; cesarean sec-
tion may be indicated when the fetus is overdeveloped;
breast feeding should always be tried and sterilization
should be considered in women with unstable diabetes
and according to the number of children the patients
already had [6]. Many of his conclusions are applied with
some modifications and adaptations until today.
Miller in 1945 reported the first observations on ob-
stetrical complications in the prediabetic period [17]. In
the 1950s many risk factors for the development of ab-
normalities in carbohydrate metabolism in pregnancy
were defined and the term gestational diabetes mellitus
(GDM) became accepted [18-21]. Soon after, screening
programs were proposed for the early detection of dia-
betes in pregnancy.
In 1949, Dr. Priscilla White working at the Joslin
Clinic in Boston, wrote a paper and proposed the
“White's Classification” that became a hallmark in the
classification of diabetes and pregnancy. This classifica-
tion was revised many times in order to separate those
patients with GDM from those with pre-existing dia-
betes. An alphabetic list was added to the original classi-
fication that took into account the age of diabetes onset,
diabetes duration and the presence of diabetes-related
complications [22].
Screening for hyperglycemia in pregnancy
In the 1960s, the screening for GDM was done by taking
patients’ history alone. The increased obstetrical risk as-
sociated with GDM, was first described by Hoet in 1954
[23]. Soon after that the National Institutes of Health
developed a program in the epidemiology of chronic dis-
eases, and a center for their study was established in
Boston, Massachusetts, under Hugh Wilkerson [24]. At
that time the role of glycosuria in pregnancy was contro-
versial, although most investigators agreed of the possi-
bility that it could be the first indicator of the presence
of diabetes mellitus.
Based on Hoet’s study [23] and in the observation of a
large group of women who were followed-up by
Dr. John B. O’Sullivan, Wilkerson and Remein [19] in
1957 proposed offering a 3-hour oral glucose tolerance
test (OGTT) for patients presenting risk factors for dia-
betes such as family history of diabetes, gestational
glycosuria and overdeveloped infants at birth. For
women without known risk factors, they proposed
determining a 1-hour blood glucose value after the inges-
tion of a 50 g glucose load. A value of 130 mg or more
was considered abnormal and a 3-hour OGTT should be
performed afterwards [19].
Jackson in 1960, wrote a review article stating that a tem-
porary abnormality in glucose tolerance during pregnancy
indicated a potentially permanent diabetes state in the
mother [25]. He also defined different stages in the devel-
opment of diabetes: prediabetes (patients with a retrospect-
ive diagnosis of diabetes and with significant presence of
risk factors for its development); chemical diabetes (asymp-
tomatic patients with abnormal glucose tolerance) and
finally overt diabetes (symptomatic patients) [25].
In order to detect any degree of carbohydrate metabo-
lism disorder early in pregnancy, several modifications
were proposed for the OGTT like the use of intravenous
tolbutamide by Unger and Madison in 1958 [26] and of
cortisone some hours before the oral glucose load by
Conn and Fajans in 1961 [27]. The obtained curves
presented much higher values than those performed
without any drug and the methodology was abandoned.
There was a great confusion with the criteria for the
definition of diabetes during pregnancy and even outside
of pregnancy, based on glucose tolerance tests, ham-
pered by different methodology to determine blood glu-
cose levels (Somogyi-Nelson and Folin-Wu in the USA
and Henederman in Europe), by the concentration of
glucose in the solution to be ingested and whether the
determination of glucose levels should be done in ven-
ous or capillary blood [4]. The Somogyi-Nelson, Folin-
Wu and Henederman assays, are not specific for glucose;
they measure all reducing substances present in the whole
blood and give results that are 15–20 mg/dl higher than
assays that measure only glucose [4].
The controversy on how to screen and diagnose GDM
was great. Using the OGTT criteria for nonpregnant
subjects, in pregnant women, the incidence of diabetes
was about one-third of the entire pregnant population.
In order to solve this problem, O’Sullivan performed
100-g OGTTs in 752 mainly second- and third-trimester
pregnant women and found with the statistician Claire
Mahan the first, second, and third standard deviation
upper limits for these glucose values [28]. These were
the first statistically based criteria for assessing glycemic
normality in pregnancy. Compared to those found in
normal individuals they had higher upper-limit values at
the 2nd and 3rd hour, consistent with an impaired glu-
cose tolerance in pregnant compared with nonpregnant
individuals. The O’Sullivan and Mahan criteria, became
the standard for diabetes detection in pregnancy for the
next decades, although they were originally formulated
to predict type 2 diabetes in the future and not to pre-
dict maternal and fetal problems in the index pregnancy
[28]. The values proposed by O’Sullivan and Mahan
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were: fasting, 110 mg/dl; 1-hour, 170 mg/dl; 2-hours,
120 mg/dl and 3-hours, 110 mg/dl (for Somogyi-Nelson
method and venous blood). Two or more abnormal
values were enough to diagnose an abnormal test [28].
These values selected by O’Sullivan and Mahan repre-
sented the mean plus two standard deviations because
they believed that the more lenient the test, for example
mean plus one standard deviation, the greater would be
the prevalence of diabetes, resulting in a long term
follow-up of these patients what would pose an eco-
nomic problem. They also believed that alerting too
many people in order to benefit a relatively few potential
diabetics would arise psychologic ill-effects [28].
Many studies such as those conducted by Pedersen
and Priscilla White, showing the importance of maternal
glucose levels in the outcomes of pregnancy in women
with diabetes have changed the focus of the importance
of diagnosing and treating these women as early as pos-
sible, not only aiming to predict the risk of type 2
diabetes in the future, but also to prevent adverse out-
comes with the mother and the fetus in the current
pregnancy [22,29].
In 1979, the National Diabetes Data Group (NDDG)
converted the values of whole blood glucose thresholds
to those approximately 14% higher plasma glucose values,
as most of the laboratory instruments started to report
plasma glucose values instead of whole blood glucose [30].
Gradually antenatal screening for hyperglycemia in
pregnancy became established but also different screen-
ing and diagnostic procedures became proposed, even in
the same country. The increasing incidence of diabetes
in the background population, the altering demographic
changes in human reproduction, the increasing preva-
lence of obesity among many other factors, resulted in
important variation in the reported prevalence. For this
reason, a series of International Colloquia on Carbohy-
drate Metabolism in Pregnancy were conducted between
1973 and 1988, four of them held in Aberdeen in
Scotland. All of them failed to reach a worldwide con-
sensus on the dose of glucose to use, how it should be
given and when blood glucose should be measured [31].
Diagnosing hyperglycemia in pregnancy
The international workshops on gestational diabetes
mellitus
Because of a growing disagreement in the best way to
screen and diagnose diabetes in pregnancy Norbet
Freinkel organized the First International Workshop on
GDM in October 1979 in Chicago; another four would
still come and also take place in Chicago. GDM was
then defined as “carbohydrate intolerance of variable se-
verity recognized for the first time in pregnancy”. The
criteria used for the diagnosis were those established by
O’ Sullivan and Mahan in 1964 [28,32,33]. It was then
recommended reinforcement in research to achieve
more accurate diagnosis, precisely define outcomes cri-
teria, correlate outcomes with maternal variables and fi-
nally find more effective therapy alternatives to control
blood glucose levels. It was also proposed that if a pa-
tient was at risk for glucose intolerance, a fasting plasma
glucose or a random glucose at least 2 hours postprandial
should be done. All women who had not been identified
as having glucose intolerance before 24 weeks gestation,
should be screened for GDM between 24–28 weeks gesta-
tion. A special attention should be given to those patients
with a fasting plasma glucose level > 105 mg/dl. In cases
of GDM, a close surveillance of the mother and the fetus
should be done; nutritional counseling, including advice
to limit intake of concentrated sweets and insulin therapy
should be established if diet alone failed to maintain a
fasting plasma glucose < 105 mg/dl and a 2-hour post-
prandial < 120 mg/dl; oral hypoglycemic agents were not
recommended. A strict control of blood glucose levels
showed to be important in reducing fetal and perinatal
morbidity and mortality [33].
The Second International Workshop on GDM was
held in October 1984. The definition of GDM developed
at the First Workshop was confirmed, adding that “the
definition applies irrespective of whether or not insulin
is used for the treatment or if the condition persists after
pregnancy. It does not exclude the possibility that the
glucose intolerance may have antedated the pregnancy”
[34]. In terms of GDM detection, it was determined that
all pregnant women should be screened for glucose in-
tolerance, since selective screening based on clinical at-
tributes or past obstetric history is inadequate. This
screening should be performed by glucose measurement
between 24–28 weeks gestation in women not identified
as having glucose intolerance before the 24th gestation
week. A 50 g oral glucose challenge test (OGCT) for
screening was proposed, regardless of last meal or time
of the day, and a venous plasma glucose cutoff of ≥ 140
mg/dl on a sample obtained one hour after the glucose
load was considered abnormal. For diagnostic purposes
it was recommended to continue the utilization of 100 g
OGTT and its interpretation according to diagnostic cri-
teria of O’Sullivan and Mahan. Capillary blood measure-
ment should not be used for diagnostic purposes. The
measurement of glycated hemoglobin was also not consid-
ered a sensitive diagnostic indicator for GDM. In terms of
management of GDM, those patients with fasting and
potprandial hyperglycemia should be considered at greater
risk for intrauterine death or neonatal mortality; they must
undergo careful antepartum fetal surveillance. It was also
mentioned by the first time that impaired carbohydrate
tolerance may develop in macrosomic offspring. The nu-
tritional counseling comprehended limitation of sucrose
intake, monitoring of maternal weight, a caloric intake
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equivalent to that of nondiabetic women of normal weight
but not so restrictive in calories. A program of moderate
exercise was also recommended [34].
The blood glucose levels should be monitored, and if
dietary management does not consistently maintain
fasting plasma glucose < 105 mg/dl and/or a 2-hour post-
prandial plasma glucose < 120 mg/dl on two or more oc-
casions within a two week interval, insulin should be
initiated, accompanied by self-monitoring of blood glu-
cose; breastfeeding should be encouraged. Finally, it was
reinforced that more than half of women with GDM will
develop permanent diabetes. In order to detect diabetes
early, an evaluation with a 2-hour, 75 g OGTT should be
performed at the first postpartum visit. Regular physical
activity should be encouraged to these patients [34].
The Third International Workshop on GDM happened
in November 1990. The previous definition of GDM was
confirmed. Screening and diagnostic criteria were also
confirmed but with some modifications: Plasma glucose
levels ≥ 200 mg/dl outside of formal OGTT, or fasting
glucose ≥ 140 mg/dl suggests a diabetic state, warranting
further investigation. A proportion of patients who
meet recommended criteria for GDM have screening
levels < 140 mg/dl and consequently the detection of
GDM requires a substantial increase in the number of
full OGTT performed. Also for diagnostic purposes, it
is to mention that adjustments for conversion of whole
blood glucose concentrations to equivalent plasma glu-
cose values may overcorrect glucose levels; for this rea-
son it is inadvisable to introduce minor corrective
modifications. One single abnormal OGTT value may
merit further evaluation since it may be associated with
increased morbidity. Fixed diagnostic criteria were sug-
gested for all populations. Macrosomia could be clinic-
ally estimated by fetal size and asymmetric growth
identified by ultrasonography, and an earlier interven-
tion could improve this outcome. In terms of long-
range implications, it was emphasized that babies born
to mothers with GDM present an increased risk of overt
diabetes later in life and an increased likelihood of
obesity, glucose intolerance and neurobehavioral and
developmental abnormalities at birth and during child-
hood [35].
In March 1997 happened the Fourth International
Workshop on GDM. The previous definition of GDM was
confirmed. It was proposed and recommended a screen-
ing strategy to identify women at low-risk (belonging to
an ethnic group with a low prevalence of GDM, having no
known diabetes in first-degree relatives, aged < 25 years,
presenting normal weight before pregnancy and at birth,
no history of abnormal glucose metabolism or of poor ob-
stetric outcome) who would not need evaluation; average
risk (should perform blood glucose testing at 24–28 weeks
using either a two-step procedure with a 50 g OGCT
followed by a diagnostic OGTT in those meeting the
threshold value in the OGCT of ≥ 140 mg/dl, or a one-
step procedure with an OGTT performed on all subjects)
as shown in Table 1, and high risk (those with at least one
or more of these risk factors: marked obesity, strong
family history of type 2 diabetes, previous history of
GDM, impaired glucose metabolism, glucosuria or be-
longing to high-risk ethnic groups such as Hispanic,
African, Native American, South or East Asian and from
Pacific Islands, or of Indigenous Australian ancestry) it
was recommended universal screening or diagnostic test-
ing using the Carpenter and Coustan criteria for interpret-
ation of the 100 g OGTT, with new cutoff values: fasting
95 mg/dL, 1h 180 mg/dL, 2h 155 mg/dL, 3 h 140 mg/dL,
and also a 75 g 2-hours OGTT with the above criteria.
They should perform blood glucose testing as soon as
feasible. If GDM is not diagnosed, blood glucose testing
should be repeated at 24-28 weeks or at any time a patient
has symptoms or signs suggestive of hyperglycemia [36].
For the first time it was recommended the use of ultra-
sound to detect congenital anomalies in patients with
GDM diagnosed in the first trimester or who presented
with fasting glucose concentrations > 120 mg/dL [36].
Some new therapeutic interventions were proposed
during pregnancy with GDM such as: ideal glycemic tar-
gets to prevent fetal risk should be lowered to capillary
glucose levels of fasting ≤ 95 mg/dL, 1 h ≤ 140 mg/dL,
and/or 2 h ≤ 120 mg/dL; the weight gain should be of
~ 7 kg for obese patients (BMI > 29 kg/m2) and greater
weight gain of up to 18 kg for underweight patients (BMI
< 19.8 kg/m2); it was recommended the use of glucose
meters that store results electronically including postpran-
dial testing as well as fasting and/or premeal testing;
measurement of pre-breakfast urine ketone for patients
on hypocaloric or carbohydrate-restricted diets. Insulin
therapy was recommended with minimally antigenic
Table 1 Screening and diagnosis of GDM in a one or
two-step approach according to ADA
SCREENING
Single step OGTT 100 or 75g For average and high
risk pregnant 24th-28th
gestation weeks
Two steps OGCT 50g If 1-hour≥
140 mg/dl Perform
an OGTT 100g
For all pregnant women
24th-28th gestation
weeks
DIAGNOSIS OGTT 100g OGTT 75g
FASTING 95 mg/dl 95 mg/dl
1-hour 180 mg/dl 180 mg/dl
2-hours 155 mg/dl 155 mg/dl
3-hours 140 mg/dl -
Criteria for GDM diagnosis= 2 altered values.
75 g OGTT does not include the 3-hour value.
A carbohydrate-rich diet with more than 150 g/ day/ 3 days before the test.
Patients should be seated and do not smoke during the test.
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insulin preparations for patients who fail glycemic goals or
show signs of excessive fetal growth. Physical activity
should be performed three times per week for at least 15
minutes [36].
In order to monitor fetal wellbeing it was recommended
maternal fetal movement counting during the last 8–10
weeks of pregnancy; in patients requiring insulin, non
stress testing from 32 weeks onward and at or near term
in those requiring only dietary management. More com-
plex fetal monitoring such as the biophysical profile or
doppler assessment of umbilical cord blood flow may be
considered when excessive or poor fetal growth are noted
or there are complicating medical problems, such as pre-
eclampsia. Fetal abdominal circumference measurements
by ultrasound at 29–33 weeks gestation are useful in iden-
tifying a large subset of patients with maternal fasting
glucose levels < 105 mg/dL who are at low risk for fetal
macrosomia at term when managed with dietary therapy
alone [36].
In terms of long-range implications and management
after pregnancy, it was noted that the progression to
type 2 diabetes within 5 years after the diagnosis of
GDM was related to gestational age, severity of GDM at
diagnosis, level of glycemia at first postpartum assess-
ment, impairment of β-cell function, obesity, and further
pregnancy. It was then recommended an evaluation of
glucose tolerance in the mother 6–12 weeks postpartum
with a 75 g OGTT; if postpartum testing does not indi-
cate diabetes, fasting plasma glucose should be evaluated
annually and in preparation for any future pregnancy.
Patients should be instructed in lifestyle behaviors to re-
duce weight and increase physical activity to reduce the
risk of subsequent diabetes; preconception counseling
should be given to address appropriate contraception and
women contemplating a future pregnancy should be ad-
vised to take supplementary folic acid to avoid risks of
congenital malformations. An increased risk of obesity
and abnormal glucose tolerance by puberty in offspring of
women with GDM was identified, and lifestyle measures
aimed at reducing or preventing obesity may decrease
these risks. Breastfeeding should also be encouraged to re-
duce the risk of obesity and possibly diabetes in the
offspring [36].
The Fifth International Workshop on GDM was held in
November 2005, under the sponsorship of the American
Diabetes Association (ADA). The meeting provided a
forum for review of new information concerning GDM in
the areas of pathophysiology, epidemiology, perinatal out-
comes, long-range implications for the mother and her
offspring, and management strategies as did the previous
four International Worshops on GDM [37]. The issues re-
garding strategies and criteria for the detection and diag-
nosis of GDM were not reviewed or discussed in detail,
since it was anticipated that the Hyperglycemia and Ad-
verse Pregnancy Outcome (HAPO) study [38] would pro-
vide data that would adopt criteria for the diagnosis of
GDM that would be based on perinatal outcomes. Thus, a
motion to continue use of the definition, classification
criteria, and strategies for detection and diagnosis of
GDM that were recommended at the Fourth Inter-
national Workshop was endorsed [36]. Minor modifi-
cations were done mainly in relation to metabolic
assessments recommended after GDM. These assess-
ments should be done as follows: a fasting or random
plasma glucose 1–3 days after delivery, to detect persist-
ent, overt diabetes; around the time of postpartum visit,
a 75-g 2-hour OGTT for the postpartum classification
of glucose metabolism; the OGTT should be repeated
one year postpartum, then tri-annually and before another
pregnancy in order to assess glucose metabolism. It was
also recommended to measure a fasting plasma glucose
annually [37].
After so many international workshops and several de-
cades of research, there is still no unified global ap-
proach for GDM diagnosis [38-43], as seen in Table 2.
The hyperglycemia and adverse pregnancy outcomes study
The objective of the Hyperglycemia and Adverse Preg-
nancy Outcome (HAPO) Study was to clarify the risk of
adverse outcomes associated with different degrees of
Table 2 Existing criteria for GDM diagnosis
Diagnostic test Blood glucose values (mg/dl) Diagnostic criteria
fasting 1-hour 2-hours 3-hours
National Diabetes Data Group, 1979 [30] 100g OGTT-whole blood 105 190 165 145 2 or more values above limit
Carpenter e Coustan,1982 [38] 100g OGTT- plasma glucose 95 180 155 140 2 or more values above limit
World Health Organization, 1998 [39] 75g OGTT- plasma glucose 126 - 140 - 1 value above limit
Brazilian Health Ministry, 2002 [40] 75g OGTT- plasma glucose 110 - 140 - 1 value above limit
ADA, 2004 [41] 100g OGTT 95 180 155 140 2 or more values above limit
American Diabetes Association, 2009 [42] 100g OGTT/ 75gOGTT 95 180 155 - 2 or more values above limit
Brazilian Health Ministry, 2002 [43] 75g OGTT- plasma glucose 95 180 155 - 2 or more values above limit
ADA, 2011 (46) and IADPSG,2010 [45] 75g OGTT- plasma glucose 92 180 153 -
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maternal glucose intolerance less severe than overt dia-
betes during pregnancy. Glucose tolerance was measured
in approximately 25,000 women from nine different coun-
tries and fifteen different centers, in a heterogeneous,
multicultural, ethnically diverse cohort of women at 24–
32 gestation weeks. Positive associations were found be-
tween higher fasting, 1- and 2-h OGTT plasma glucose
concentrations and birth weight >90th percentile and
cord serum C-peptide >90th percentile, primary cesarean
delivery, clinical neonatal hypoglycemia, preterm delivery,
shoulder dystocia or birth injury, intensive neonatal care,
hyperbilirubinemia, and preeclampsia, as well as with
newborn adiposity [44].
The associations of maternal glycemia with perinatal
outcomes were continuous with no obvious thresholds
at which risks increased, it was evident that a consensus
was required to translate these results into clinical prac-
tice. Many other issues had then to be addressed such as
the importance to have all three OGTT glucose mea-
surements (fasting, 1-, and 2-h-post load values) in the
OGTT since the individual OGTT glucose measures were
not highly correlated, and no single measure was clearly
superior to each other in predicting the primary out-
comes. It was necessary to find out the threshold at or
above which the risk of adverse outcomes was too high.
The international association of diabetes and pregnancy
study groups
The International Association of Diabetes and Pregnancy
Study Groups (IADPSG) was formed in 1998 to facilitate
collaboration between the various regional and national
groups that have a primary or significant focus on dia-
betes and pregnancy. The IADPSG sponsored an “Inter-
national Workshop Conference on Gestational Diabetes
Diagnosis and Classification” in Pasadena, CA on June
2008 to initiate the process of a consensus development
based on the data found in the HAPO study, associating
maternal glycemia with perinatal and long-term out-
comes in the offspring. Under the coordination from the
Consensus Panel Steering Committee/Writing Group,
the Panel reviewed further HAPO Study results provided
by the HAPO Study Data Coordinating Center and the
Consensus Panel has formulated the “Recommendations
on the Diagnosis and Classification of Hyperglycemia in
Pregnancy” which was soon after published, with new
thresholds for the diagnosis of GDM [45]. It was then
expected that this report would be considered by all of
the major diabetes organizations and would serve as the
basis for internationally uniform criteria for the diagno-
sis and classification of diabetes in pregnancy [45].
The new diagnostic criteria were soon adopted by many
pre-eminent diabetes organizations such as the American
Diabetes Association [46] and the Brazilian diabetes Soci-
ety [47]. Despite the clear evidences that the HAPO study
has shown on how harmful can even slightly altered blood
glucose levels be, it has been found a resistance in the
adoption of the new criteria by many diabetes organiza-
tions stating that these new criteria would increase the in-
cidence of GDM from around 7% to 18.7%, and that the
greater the prevalence of diabetes diagnosis, a longer term
follow-up of these patients would be needed and would
pose an economic problem, and also that alerting too
many people in order to benefit a relatively few potential
diabetics would arise psychologic ill-effects. These are the
same arguments used by O’Sullivan and Mahan to select
the upper standard deviation when they first described the
OGTT in 1964. It seems that we did not have too much
progress in the last decades.
Conclusions
After several international workshops and many decades
of research, there is still no unified global approach to
GDM, as seen in Table 2. Most countries have their own
diabetes associations each one with 1 to 3 diabetes soci-
eties as an International Diabetes Federation member
[48]. These societies often have their own guidelines for
GDM, which may be very similar or markedly different,
and often, no guideline is proposed. The problem of
GDM is the lack of an international consensus among
these diabetes organizations. There is a wide diversity in
the methods used in most countries due to multiple rea-
sons. Health providers often prefer to use alternate cri-
teria, follow the recommendation of a diabetes or health
organization from another country and often there is
disagreement between the country’s national diabetes
organization, its local health society, and its regional ob-
stetric organization, with each one recommending differ-
ent approaches for screening and diagnosing GDM. It
would be of interest of pregnant patients the formulation
of unified universal guidelines for GDM. A consensus
could be achieved with the evidence based gained from
the data obtained in recent trials. It is time to an agree-
ment about one global guideline for GDM.
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